Clinical and Immunological Effects in Patients with Advanced Non-Small Cell Lung-Cancer after Vaccination with Dendritic Cells Exposed to an Allogeneic Tumor Cell Lysate*

Lotte Engell-Noerregaard; Pia Kvistborg; Mai-Britt Zocca; Ayako W. Pedersen; Mogens Helweg Claesson; Anders Mellemgaard

doi:10.4236/wjv.2013.32011

Clinical and Immunological Effects in Patients with Advanced Non-Small Cell Lung-Cancer after Vaccination with Dendritic Cells Exposed to an Allogeneic Tumor Cell Lysate*

Lotte Engell-Noerregaard, Pia Kvistborg, Mai-Britt Zocca, Ayako W. Pedersen, Mogens Helweg Claesson, Anders Mellemgaard

Abstract

We evaluated the clinical and immunological effects of dendritic cell (DC) vaccination of patients with NSCLC. Autologous DCs were pulsed with a MAGE containing allogeneic melanoma cell lysate (MelCancerVac®, Dandrit Biotech, Copenhagen, Denmark). Imiquimod cream, proleukin and celecoxib were used as adjuvants to the vaccines. The objective of the study was to evaluate specific T cell response in vitro by IFN EliSpot. Secondary objec- tives were overall survival, response and quality of life (QoL). Results: Twenty-two patients initiated the vaccination program consisting of ten vaccinations. Seven patients remained in stable disease (SD) three months after the first vac- cination. After ten vaccinations (six months), four patients still showed SD and continued vaccinations on a monthly basis. These four patients received a total of 12, 16, 26 and 35 vaccinations, respectively. Five patients showed an un- expectedly prolonged survival. The treatment was well tolerated and only minor adverse events were reported. Quality of life did not change during the study period. In four of the seven patients with SD, vaccine-specific T cells were de- tected by IFNγ EliSpot assays, whereas only one patient with progressive disease (PD) showed vaccine-specific re- sponses. Conclusion: This DC-based vaccine trial has indicated a correlation between vaccine-specific immunity and sustained SD. Furthermore, we observed an unexpectedly prolonged survival in some patients, which may indicate de- layed effect of DC vaccination after completion of the treatment. A prospective randomized phase-IIb or -III is needed to further evaluate the use of MelCancerVac® vaccine treatment in patients with progressive NSCLC.

Originalsprog	Engelsk
Tidsskrift	World Journal of Vaccines
Vol/bind	3
Udgave nummer	2
Sider (fra-til)	68-76
Antal sider	9
ISSN	2160-5815
DOI	https://doi.org/10.4236/wjv.2013.32011
Status	Udgivet - 2013

Emneord

Det Sundhedsvidenskabelige Fakultet
NSCLC
Dendritic Cells
Vaccination
Tumor Lysate

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.4236/wjv.2013.32011

http://dx.doi.org/10.4236/wjv.2013.32011

Citationsformater

Clinical and Immunological Effects in Patients with Advanced Non-Small Cell Lung-Cancer after Vaccination with Dendritic Cells Exposed to an Allogeneic Tumor Cell Lysate*. / Engell-Noerregaard, Lotte; Kvistborg, Pia; Zocca, Mai-Britt et al.

I: World Journal of Vaccines, Bind 3, Nr. 2, 2013, s. 68-76.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{bb648b1b99a94dd69a3955c0b1e700ba,

title = "Clinical and Immunological Effects in Patients with Advanced Non-Small Cell Lung-Cancer after Vaccination with Dendritic Cells Exposed to an Allogeneic Tumor Cell Lysate*",

abstract = "Background: We evaluated the clinical and immunological effects of dendritic cell (DC) vaccination of patients with NSCLC. Autologous DCs were pulsed with a MAGE containing allogeneic melanoma cell lysate (MelCancerVac{\textregistered}, Dandrit Biotech, Copenhagen, Denmark). Imiquimod cream, proleukin and celecoxib were used as adjuvants to the vaccines. The objective of the study was to evaluate specific T cell response in vitro by IFN EliSpot. Secondary objec- tives were overall survival, response and quality of life (QoL). Results: Twenty-two patients initiated the vaccination program consisting of ten vaccinations. Seven patients remained in stable disease (SD) three months after the first vac- cination. After ten vaccinations (six months), four patients still showed SD and continued vaccinations on a monthly basis. These four patients received a total of 12, 16, 26 and 35 vaccinations, respectively. Five patients showed an un- expectedly prolonged survival. The treatment was well tolerated and only minor adverse events were reported. Quality of life did not change during the study period. In four of the seven patients with SD, vaccine-specific T cells were de- tected by IFNγ EliSpot assays, whereas only one patient with progressive disease (PD) showed vaccine-specific re- sponses. Conclusion: This DC-based vaccine trial has indicated a correlation between vaccine-specific immunity and sustained SD. Furthermore, we observed an unexpectedly prolonged survival in some patients, which may indicate de-layed effect of DC vaccination after completion of the treatment. A prospective randomized phase-IIb or -III is needed to further evaluate the use of MelCancerVac{\textregistered} vaccine treatment in patients with progressive NSCLC.",

keywords = "Faculty of Health and Medical Sciences, NSCLC, Dendritic Cells, Vaccination, Tumor Lysate",

author = "Lotte Engell-Noerregaard and Pia Kvistborg and Mai-Britt Zocca and Pedersen, {Ayako W.} and Claesson, {Mogens Helweg} and Anders Mellemgaard",

year = "2013",

doi = "10.4236/wjv.2013.32011",

language = "English",

volume = "3",

pages = "68--76",

journal = "World Journal of Vaccines",

issn = "2160-5815",

publisher = "Scientific Research Publishing, Inc.",

number = "2",

}

TY - JOUR

T1 - Clinical and Immunological Effects in Patients with Advanced Non-Small Cell Lung-Cancer after Vaccination with Dendritic Cells Exposed to an Allogeneic Tumor Cell Lysate*

AU - Engell-Noerregaard, Lotte

AU - Kvistborg, Pia

AU - Zocca, Mai-Britt

AU - Pedersen, Ayako W.

AU - Claesson, Mogens Helweg

AU - Mellemgaard, Anders

PY - 2013

Y1 - 2013

N2 - Background: We evaluated the clinical and immunological effects of dendritic cell (DC) vaccination of patients with NSCLC. Autologous DCs were pulsed with a MAGE containing allogeneic melanoma cell lysate (MelCancerVac®, Dandrit Biotech, Copenhagen, Denmark). Imiquimod cream, proleukin and celecoxib were used as adjuvants to the vaccines. The objective of the study was to evaluate specific T cell response in vitro by IFN EliSpot. Secondary objec- tives were overall survival, response and quality of life (QoL). Results: Twenty-two patients initiated the vaccination program consisting of ten vaccinations. Seven patients remained in stable disease (SD) three months after the first vac- cination. After ten vaccinations (six months), four patients still showed SD and continued vaccinations on a monthly basis. These four patients received a total of 12, 16, 26 and 35 vaccinations, respectively. Five patients showed an un- expectedly prolonged survival. The treatment was well tolerated and only minor adverse events were reported. Quality of life did not change during the study period. In four of the seven patients with SD, vaccine-specific T cells were de- tected by IFNγ EliSpot assays, whereas only one patient with progressive disease (PD) showed vaccine-specific re- sponses. Conclusion: This DC-based vaccine trial has indicated a correlation between vaccine-specific immunity and sustained SD. Furthermore, we observed an unexpectedly prolonged survival in some patients, which may indicate de-layed effect of DC vaccination after completion of the treatment. A prospective randomized phase-IIb or -III is needed to further evaluate the use of MelCancerVac® vaccine treatment in patients with progressive NSCLC.

AB - Background: We evaluated the clinical and immunological effects of dendritic cell (DC) vaccination of patients with NSCLC. Autologous DCs were pulsed with a MAGE containing allogeneic melanoma cell lysate (MelCancerVac®, Dandrit Biotech, Copenhagen, Denmark). Imiquimod cream, proleukin and celecoxib were used as adjuvants to the vaccines. The objective of the study was to evaluate specific T cell response in vitro by IFN EliSpot. Secondary objec- tives were overall survival, response and quality of life (QoL). Results: Twenty-two patients initiated the vaccination program consisting of ten vaccinations. Seven patients remained in stable disease (SD) three months after the first vac- cination. After ten vaccinations (six months), four patients still showed SD and continued vaccinations on a monthly basis. These four patients received a total of 12, 16, 26 and 35 vaccinations, respectively. Five patients showed an un- expectedly prolonged survival. The treatment was well tolerated and only minor adverse events were reported. Quality of life did not change during the study period. In four of the seven patients with SD, vaccine-specific T cells were de- tected by IFNγ EliSpot assays, whereas only one patient with progressive disease (PD) showed vaccine-specific re- sponses. Conclusion: This DC-based vaccine trial has indicated a correlation between vaccine-specific immunity and sustained SD. Furthermore, we observed an unexpectedly prolonged survival in some patients, which may indicate de-layed effect of DC vaccination after completion of the treatment. A prospective randomized phase-IIb or -III is needed to further evaluate the use of MelCancerVac® vaccine treatment in patients with progressive NSCLC.

KW - Faculty of Health and Medical Sciences

KW - NSCLC

KW - Dendritic Cells

KW - Vaccination

KW - Tumor Lysate

U2 - 10.4236/wjv.2013.32011

DO - 10.4236/wjv.2013.32011

M3 - Journal article

SN - 2160-5815

VL - 3

SP - 68

EP - 76

JO - World Journal of Vaccines

JF - World Journal of Vaccines

IS - 2

ER -

Clinical and Immunological Effects in Patients with Advanced Non-Small Cell Lung-Cancer after Vaccination with Dendritic Cells Exposed to an Allogeneic Tumor Cell Lysate*

Abstract

Emneord

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater